polyclonal anti-pax8 rabbit antibody Search Results


polyclonal anti-pax8 rabbit antibody  (PeproTech)
90
PeproTech polyclonal anti-pax8 rabbit antibody
Profiling data available from the 4 HGSOC patient cell cultures ex vivo
Polyclonal Anti Pax8 Rabbit Antibody, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyclonal anti-pax8 rabbit antibody/product/PeproTech
Average 90 stars, based on 1 article reviews
polyclonal anti-pax8 rabbit antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Profiling data available from the 4 HGSOC patient cell cultures ex vivo

Journal: Briefings in Bioinformatics

Article Title: Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer

doi: 10.1093/bib/bbab272

Figure Lengend Snippet: Profiling data available from the 4 HGSOC patient cell cultures ex vivo

Article Snippet: To detect the surviving cells of different subpopulations at the end of drug treatment, the cells were fixed with 4% paraformaldehyde and immunostained with polyclonal anti-PAX8 rabbit antibody (Peprotech) using automated liquid handling.

Techniques: Imaging, Cytometry, Viability Assay, Sequencing, Ex Vivo

Construction and validation of the multi-patient and patient-specific predictive models. For a given sample, each drug was associated with a feature vector corresponding both to its drug-target profile and to the gene expression profile (decomposed from bulk RNA-seq) and point mutation detections (extracted from WGS) of the particular sample (left). In each iteration of 10-fold CV, 90% of the drug-sample feature matrix were used for training and the remaining 10% was used for testing of the monotherapy prediction accuracy, either using the PAX8+ and PAX8- samples from a single patient case (right, Patient-specific model), or all the patient samples (multi-patient model).

Journal: Briefings in Bioinformatics

Article Title: Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer

doi: 10.1093/bib/bbab272

Figure Lengend Snippet: Construction and validation of the multi-patient and patient-specific predictive models. For a given sample, each drug was associated with a feature vector corresponding both to its drug-target profile and to the gene expression profile (decomposed from bulk RNA-seq) and point mutation detections (extracted from WGS) of the particular sample (left). In each iteration of 10-fold CV, 90% of the drug-sample feature matrix were used for training and the remaining 10% was used for testing of the monotherapy prediction accuracy, either using the PAX8+ and PAX8- samples from a single patient case (right, Patient-specific model), or all the patient samples (multi-patient model).

Article Snippet: To detect the surviving cells of different subpopulations at the end of drug treatment, the cells were fixed with 4% paraformaldehyde and immunostained with polyclonal anti-PAX8 rabbit antibody (Peprotech) using automated liquid handling.

Techniques: Biomarker Discovery, Plasmid Preparation, Gene Expression, RNA Sequencing, Mutagenesis

Coverage of PAX8 marker gene detection using deconvoluted RNA-seq data

Journal: Briefings in Bioinformatics

Article Title: Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer

doi: 10.1093/bib/bbab272

Figure Lengend Snippet: Coverage of PAX8 marker gene detection using deconvoluted RNA-seq data

Article Snippet: To detect the surviving cells of different subpopulations at the end of drug treatment, the cells were fixed with 4% paraformaldehyde and immunostained with polyclonal anti-PAX8 rabbit antibody (Peprotech) using automated liquid handling.

Techniques: Marker

Overlap of marker genes detected in EOC0939_pAsc scRNA-seq data versus fresh tumor samples. ( A ) PAX8+ markers, ( B ) PAX8- markers. The marker genes were detected from the scRNA-seq data with Wilcoxon test, using adjusted P < 0.01 and log fold-change > 1 cutoffs. Fresh tumor, scRNA-seq from fresh dissociated tissue; before culture, scRNA-seq from cryopreserved dissociated tissue; after culture, scRNA-seq from cultured cryopreserved dissociated tissue after 1 week in culture.

Journal: Briefings in Bioinformatics

Article Title: Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer

doi: 10.1093/bib/bbab272

Figure Lengend Snippet: Overlap of marker genes detected in EOC0939_pAsc scRNA-seq data versus fresh tumor samples. ( A ) PAX8+ markers, ( B ) PAX8- markers. The marker genes were detected from the scRNA-seq data with Wilcoxon test, using adjusted P < 0.01 and log fold-change > 1 cutoffs. Fresh tumor, scRNA-seq from fresh dissociated tissue; before culture, scRNA-seq from cryopreserved dissociated tissue; after culture, scRNA-seq from cultured cryopreserved dissociated tissue after 1 week in culture.

Article Snippet: To detect the surviving cells of different subpopulations at the end of drug treatment, the cells were fixed with 4% paraformaldehyde and immunostained with polyclonal anti-PAX8 rabbit antibody (Peprotech) using automated liquid handling.

Techniques: Marker, Cell Culture